CBT-295
Product Specifications
UNSPSC Description
CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy[1].
Target Antigen
Interleukin Related; TGF-beta/Smad
Type
Reference compound
Related Pathways
Immunology/Inflammation;Stem Cell/Wnt;TGF-beta/Smad
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/cbt-295.html
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1C=C(C)N(CCCCC)C2=NC(C3=CC=C(Cl)C=C3)=CN12
Molecular Weight
329.82
References & Citations
[1]Roy S, et al. Effect of an Autotaxin Inhibitor, 2-(4-Chlorophenyl)-7-methyl-8-pentylimidazo [1, 2-a] Pyrimidin-5 (8 H)-one (CBT-295), on Bile Duct Ligation-Induced Chronic Liver Disease and Associated Hepatic Encephalopathy in Rats[J]. ACS Pharmacology & Translational Science, 2024.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-169004/CBT-295-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-169004/CBT-295-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
